Nonspecific binding of drugs to human liver microsomes

British Journal of Clinical Pharmacology

Volumn 49, Issue 5, 2000, Pages 453-461

  McLure, James A ^a   Miners, John O ^a   Birkett, Donald J ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Human liver microsomes; In vitro clearance prediction; In vitro drug metabolism kinetics; Nonspecific binding

Indexed keywords

AMIODARONE; AMITRIPTYLINE; CAFFEINE; NAPROXEN; NORTRIPTYLINE; PHENYTOIN; TOLBUTAMIDE;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; ENZYME KINETICS; EQUILIBRIUM DIALYSIS; HUMAN; HUMAN TISSUE; IONIZATION; LIPOPHILICITY; LIVER MICROSOME; MICROSOME MEMBRANE; PRIORITY JOURNAL;

AMITRIPTYLINE; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MODELS, BIOLOGICAL; NORTRIPTYLINE;

EID: 0034010664     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00193.x     Document Type: Article

References (34)

1. Dirkett DJ, Mackenzie PI, Veronese ME, Miners JO. In vitro approaches can predict human drug metabolism. Trends Pliannacol Sei 1993; 14: 292-294.
2. Miners JO, Veronese ME, Dirkett DJ. In vitro approaches for the prediction of human drug metabolism. Ann Reports Med Chem 1994; 29: 307-315.
3. Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Phannacokin 1998; 35: 361-390.
4. Houston DJ. Utility of m vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pliannacol 1994; 49: 1469-1479.
5. Iwatsubo T, Hirota N, Ooie T, et al. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biophann Drug Dispos 1996; 17: 273-310.
6. Tucker GT. The rational selection of drug interaction studies: implications of recent advances in drug metabolism. lut J Clin Phann Tlier Toxicol 1992; 11: 550-553.
7. Obach RS. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine and propranolol. Dmg Metab Dispos 1997; 25: 1359-1369.
8. Obach RS. The importance of nonspecific binding in HI vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Dmg Metab Dispos 1996; 24: 1047-1049.
9. Chiba M, Fujita S, Suzuki T. Pharmacokinetic correlation between in vitro hepatic microsomal enzyme kinetics and in vivo metabolism of imipramine and desipramine in rats. J Pharm Sei 1990; 79: 281-287.
10. Robson RA, Matthews AP, Minen JO, et al. Characterisation of theophyUine metabolism in human liver microsomes. Br J Clin Pliarmacol 1987; 24: 293-300.
11. Lowry OH, Rosenberg NJ, Farr AL, Randall RJ. Protein measurement with the Polin Phenol Reagent. J Biol Chem 1951; 193: 265-275.
12. Anonymous. Tlie Pharmaceutical Codex, llth edn. London. The Pharmaceutical Press, 1979: 646-648.
13. Holford NHG. MK Model. A tool for microcomputers. Pharmacokinetic evalution and comparison with standard computer programs. Clin Exp Pliarmacol Physiol 1985; Suppl 9: 95.
14. Tassaneeyakul W, Mohamed Z, Dirkett DJ, et al. Caffeine as a probe for human cytochromes P450: validation using cDNA expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pliarinacogcnetics 1992; 2: 173-183.
15. SchmiderJ, Greenblatt DJ, Harmatz JS, von Moltke LL, Shader RI. N-demethylation of amitriptyline in vitro: Role of cytochrome P450,3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pliarmacol Exp Tlier 1995; 275: 592-597.
16. Mellström B, Dertilsson C, Birgersson M, Göransson M, von Bahr C. E- and Z-10-hydroxylation of nortriptyline by human liver microsomes -methods and characterization. Dnig Metab Dispos 1983; 11: 115-119.
17. Fabre F, Julian B, Saint-Aubert B, Joyeux H, Berger Y. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Mctab Dispos 1993; 21: 978-985.
18. Miners JO, Coulter S, Tukey RH, Veronese ME, Birkett DJ. Cytochromes P450 1A2 and 2C9 are responsible for the hepatic O-demethylation of R- and S-naproxen. Biochem Phantiacol 1996; 51: 1003-1008.
19. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pliarmacol 1988; 37: 1137-1144.
20. Doecke CJ, Veronese ME, Pond SM, et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. BrJ Clin Pliarmacol 1991; 31: 125-130.
21. max and Km values: implications for clinical correlation. J Pliarmacol Exp Tlier 1997; 282: 391-396.
22. Carlile DJ, Hakooz N, Bayliss MK, Houston JB. Microsomal prediction of m vivo clearance of CYP2C9 substrates in humans. BrJ Clin Phannacol 1999; 47: 625-635.
23. Baarnhielm C, Dahlback H, Skanberg I. In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Phannacol Toxicol 1986; 59: 113-122.
24. von Moltke LL, Greenblatt DJ, Cotreau-Dibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions m vivo.] Phannacol Exp Tlier 1993; 268: 1278-1283.
25. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychophannacol 1995; 15: 125-131.
26. Andersson T, Miners JO, Veronese ME, Birkett DJ. Diazepam metabolism by human liver microsomes is mediated by S-mephenytoin hydroxylase and CYP3A isoforms. DrJ Clin Phannacol 1994; 38: 131-137.
27. Schwab GE, Raucy JL, Johnson EF. Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by a-naphthoflavone. Mol Phannacol 1988; 33: 493-199.
28. Ueng YF, Kuwabara T, Chun YJ, Guengerich FP. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 1997; 36: 370-381.
29. Korzekwa KR, Krishnamachary N, Shou M, et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998; 37: 4137-4147.
30. MäenpääJ, Hall SD, Ring BJ, Strom SC, Wrighton SA. Human cytochrome P4503A (CYP3A) mediated midazolam metabolism -the effect of assay conditions and regioselective stimulation by a-naphthoflavone, terfenadine and testosterone. Phannacogctietics 1998; 8: 137-155.
31. Domanski TL, LiuJ, Harlow GR, HalpertJR. Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and a-naphthoflavone stimulation. Arch Biochcm Biophys 1998; 350: 223-232.
32. Ekins S, Ring BJ, Binkley SN, Hall SD, Wrighton SA. Autoactivation and activation of the cytochrome P450s. IntJ Clin Phannacol Tlier 1998; 36: 642-651.
33. Ekins S, 'vandenBranden M, Ring SJ, Wrighton SA. Examination of purported probes of human CYP2B6. Phannacogenctics 1997; 7: 165-179.
34. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of GYP 2C19 and 3A4.J Clin Phannacol 1998; 38: 112-121.